| Literature DB >> 360331 |
H Furue, T Komita, I Nakao, I Furukawa, T Kanko, T Yokoyama.
Abstract
Aclacinomycin is a new anthracycline analog of adriamycin and daunomycin. Aclacinomycin contains three sugars. The drug has been studied in 22 cases in a phase 1 type of trial on a schedule 20 mg i.v. every other day up to a total of 300 mg. Toxicity has consisted of myelosuppression, nausea and vomiting, and transient hepatic disturbances. Evidence of clinical activity was observed in several cases including a case of breast cancer and gastric cancer. Although no full patial remissions were recorded, further study is continuing.Entities:
Mesh：
Substances：
Year: 1978 PMID： 360331 DOI： 10.1007/978-3-642-81219-4_22
Source DB: PubMed Journal: Recent Results Cancer Res ISSN： 0080-0015